Does initiating SGLT2 inhibitors at an early stage of heart failure admission really reduce cardiovascular mortality and first rehospitalization? A meta-analysis of randomized controlled trials
Acute heart failure (HF) patients are at high risk, especially in the first three months following discharge, when rehospitalizations are 30% common and mortality can be close to 10%. Although sodium-glucose cotransporter-2 (SGLT2) inhibitors are essential for treating heart failure, their benefit when initiated...